

Disclosures

Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Baron and Bud	Other - <i>Expert Witness</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Bayer	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
BMS	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Cleveland Clinic	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Eli Lilly and Company	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Haemonetics	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Hikari Dx	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Idorsia	Research/Research Grants	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
Instrumentation Labs	Research/Research Grants	Significant (>= \$5,000)	
LabCorp Drug Development	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Medforce	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	<i>Stable Ischemic Heart Disease</i>
Prolocor	Research/Research Grants	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Recor	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine</i>
Recor Medical	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Web MD Medscape	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Wolters Kluwer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	Clopidogrel	Third Party	Clopidogrel	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 6/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 7/21/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.